8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Nov 3, 2025·SEC
Biodesix, Inc.(BDSX)Earnings, Financials & Key Ratios
BDSX•NASDAQ
Price updated Jun 19, 2026
AboutBiodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.Show more
- Revenue$88M+24.1%
- EBITDA-$22M+23.5%
- Net Income-$35M+17.9%
- EPS (Diluted)-4.67+29.2%
- Gross Margin75.25%-3.7%
- EBITDA Margin-25.09%+38.4%
- Operating Margin-31.5%+34.9%
- Net Margin-39.85%+33.8%
- ROE-383.09%-13.6%
BDSX Key Insights
Biodesix, Inc. (BDSX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Strong 5Y sales CAGR of 14.2%
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 16.5% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BDSX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BDSX Price & Volume
Biodesix, Inc. (BDSX) stock price & volume — 10-year historical chart
Loading chart...
BDSX Growth Metrics
Biodesix, Inc. (BDSX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years14.2%
3 Years32.31%
TTM29.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30%
Return on Capital
10 Years-62.54%
5 Years-58.05%
3 Years-47.93%
Last Year-36.44%
BDSX Recent Earnings
Biodesix, Inc. (BDSX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.81+35.7%
$1.26
Rev
$26M+10.5%
$23M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.49+53.3%
$1.05
Rev
$29M+11.8%
$26M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$1.16+27.5%
$1.60
Rev
$22M-17.1%
$26M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.60-14.3%
$1.40
Rev
$20M+8.4%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.81vs $1.26+35.7% | $26Mvs $23M+10.5% |
| Q1 2026 | Feb 26, 2026 | $0.49vs $1.05+53.3% | $29Mvs $26M+11.8% |
| Q4 2025 | Nov 3, 2025 | $1.16vs $1.60+27.5% | $22Mvs $26M-17.1% |
| Q3 2025 | Aug 7, 2025 | $1.60vs $1.40-14.3% | $20Mvs $18M+8.4% |
Based on last 12 quarters of dataView full earnings history →
BDSX Peer Comparison
Biodesix, Inc. (BDSX) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 VCYT | 4.28B | 53.63 | 65.40 | 16.01% | 16.25% | 6.86% | 0.03 | |
 ONCO | 593.27K | 0.94 | -0.20 | -67.7% | -13.2% | -105.46% | 0.00 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 FLGT | 535.45M | 18.00 | -9.14 | 13.83% | -18.75% | -5.42% | 0.00 |
Compare BDSX vs Peers
Biodesix, Inc. (BDSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BDSX Income Statement
Biodesix, Inc. (BDSX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 20.43M | 24.55M | 45.56M | 54.51M | 38.21M | 49.09M | 71.32M | 88.5M | 96.1M |
Revenue Growth % | - | 20.16% | 85.55% | 19.64% | -29.89% | 28.46% | 45.3% | 24.08% | 29.05% |
Cost of Goods Sold | 4.41M | 6.07M | 22M | 30.52M | 14.15M | 13.01M | 15.57M | 21.91M | 13.02M |
COGS % of Revenue | 21.56% | 24.74% | 48.29% | 55.99% | 37.04% | 26.5% | 21.83% | 24.75% | - |
Gross Profit | 16.03M▲ 0% | 18.48M▲ 15.3% | 23.56M▲ 27.5% | 23.99M▲ 1.8% | 24.06M▲ 0.3% | 36.08M▲ 50.0% | 55.75M▲ 54.5% | 66.59M▲ 19.5% | 57.52M▲ 0% |
Gross Margin % | 78.44% | 75.26% | 51.71% | 44.01% | 62.96% | 73.5% | 78.17% | 75.25% | 59.86% |
Gross Profit Growth % | - | 15.3% | 27.5% | 1.82% | 0.29% | 49.96% | 54.53% | 19.45% | - |
Operating Expenses | 34.09M | 45.22M | 46.49M | 64.93M | 74.64M | 77.42M | 90.25M | 94.36M | 108.02M |
OpEx % of Revenue | 166.83% | 184.18% | 102.05% | 119.12% | 195.34% | 157.72% | 126.53% | 106.62% | - |
Selling, General & Admin | 25.9M | 30.64M | 34.86M | 50.52M | 61.46M | 67.39M | 80.45M | 87.55M | 91.36M |
SG&A % of Revenue | 126.76% | 124.78% | 76.51% | 92.68% | 160.84% | 137.28% | 112.8% | 98.92% | - |
Research & Development | 8.19M | 10.47M | 10.82M | 12.79M | 13.1M | 9.99M | 9.56M | 12M | 12.42M |
R&D % of Revenue | 40.07% | 42.64% | 23.75% | 23.46% | 34.29% | 20.35% | 13.4% | 13.56% | - |
Other Operating Expenses | 0 | 4.11M | 818K | 1.62M | 81K | 44K | 238K | -5.19M | 1.03M |
Operating Income | -23.46M▲ 0% | -26.74M▼ 14.0% | -22.93M▲ 14.2% | -40.94M▼ 78.5% | -50.59M▼ 23.6% | -41.34M▲ 18.3% | -34.5M▲ 16.6% | -27.87M▲ 19.2% | -24.94M▲ 0% |
Operating Margin % | -114.82% | -108.92% | -50.34% | -75.11% | -132.39% | -84.22% | -48.37% | -31.5% | -25.95% |
Operating Income Growth % | - | -13.98% | 14.24% | -78.51% | -23.56% | 18.28% | 16.55% | 19.2% | - |
EBITDA | -21.72M | -23.95M | -20.03M | -37.76M | -44.74M | -35.84M | -29.04M | -22.2M | -20.77M |
EBITDA Margin % | -106.31% | -97.54% | -43.97% | -69.28% | -117.09% | -73% | -40.72% | -25.09% | -21.61% |
EBITDA Growth % | - | -10.25% | 16.36% | -88.52% | -18.49% | 19.91% | 18.96% | 23.55% | 23.3% |
D&A (Non-Cash Add-back) | 1.74M | 2.79M | 2.9M | 3.18M | 5.84M | 5.51M | 5.46M | 5.67M | 4.17M |
EBIT | -23.25M | -27.72M | -23.75M | -38.65M | -57.38M | -42.61M | -34.67M | -27.55M | -18.13M |
Net Interest Income | -2.89M | -2.95M | -7.6M | -4.51M | -8.07M | -9.54M | -8.26M | -7.72M | -6.03M |
Interest Income | 24K | 55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 2.92M | 3.01M | 7.6M | 4.51M | 8.07M | 9.54M | 8.26M | 7.72M | 4.05M |
Other Income/Expense | -2.71M | -3.98M | -8.42M | -2.22M | -14.86M | -10.8M | -8.43M | -7.39M | -7.02M |
Pretax Income | -26.17M▲ 0% | -30.73M▼ 17.4% | -31.35M▼ 2.0% | -43.16M▼ 37.7% | -65.45M▼ 51.6% | -52.15M▲ 20.3% | -42.93M▲ 17.7% | -35.27M▲ 17.9% | -31.96M▲ 0% |
Pretax Margin % | -128.06% | -125.15% | -68.81% | -79.18% | -171.27% | -106.23% | -60.19% | -39.85% | -33.26% |
Income Tax | 211K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.81% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -26.17M▲ 0% | -30.73M▼ 17.4% | -31.35M▼ 2.0% | -43.16M▼ 37.7% | -65.45M▼ 51.6% | -52.15M▲ 20.3% | -42.93M▲ 17.7% | -35.27M▲ 17.9% | -31.96M▲ 0% |
Net Margin % | -128.06% | -125.15% | -68.81% | -79.18% | -171.27% | -106.23% | -60.19% | -39.85% | -33.26% |
Net Income Growth % | - | -17.43% | -2.03% | -37.67% | -51.64% | 20.32% | 17.67% | 17.86% | 20.93% |
Net Income (Continuing) | -26.17M | -30.73M | -31.35M | -43.16M | -65.45M | -52.15M | -42.93M | -35.27M | -31.96M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -19.80▲ 0% | -0.67▲ 96.6% | -6.48▼ 867.2% | -31.60▼ 387.7% | -31.00▲ 1.9% | -12.80▲ 58.7% | -6.60▲ 48.4% | -4.67▲ 29.2% | -3.31▲ 0% |
EPS Growth % | - | 96.62% | -867.16% | -387.65% | 1.9% | 58.71% | 48.44% | 29.24% | 30% |
EPS (Basic) | -19.80 | -0.67 | -6.48 | -31.60 | -31.00 | -12.80 | -6.60 | -4.67 | - |
Diluted Shares Outstanding | 1.33M | 45.71M | 4.84M | 1.37M | 2.11M | 4.11M | 6.48M | 7.55M | 9.66M |
Basic Shares Outstanding | 1.33M | 45.71M | 4.84M | 1.37M | 2.11M | 4.11M | 6.48M | 7.55M | 9.66M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BDSX Balance Sheet
Biodesix, Inc. (BDSX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.91M | 12.7M | 86.14M | 43.61M | 53.33M | 39.68M | 39.48M | 32.52M | 40.91M |
Cash & Short-Term Investments | 5.91M | 5.29M | 62.13M | 32.71M | 43.09M | 26.28M | 26.25M | 18.99M | 25.57M |
Cash Only | 5.91M | 5.29M | 62.13M | 32.71M | 43.09M | 26.28M | 26.25M | 18.99M | 25.57M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.89M | 5.29M | 15.3M | 3.66M | 5.07M | 7.68M | 8.6M | 9.04M | 9.5M |
Days Sales Outstanding | 33.8 | 78.67 | 122.61 | 24.48 | 48.38 | 57.1 | 44.03 | 37.27 | 36.71 |
Inventory | 700K | 800K | 3.2M | 2.9M | 1.4M | 1.4M | 0 | 0 | 0 |
Days Inventory Outstanding | 57.99 | 48.07 | 53.1 | 34.68 | 36.1 | 39.28 | - | - | 9.81 |
Other Current Assets | 1.41M | 1.32M | 8.71M | 7.25M | 5.18M | 4.32M | 4.64M | 4.5M | 5.84M |
Total Non-Current Assets | 29.14M | 28.93M | 34.93M | 32.48M | 39.57M | 59.41M | 57.76M | 54.96M | 53.73M |
Property, Plant & Equipment | 1.39M | 2.12M | 3.18M | 4.18M | 8.82M | 29.61M | 29.59M | 27.81M | 27.38M |
Fixed Asset Turnover | 14.72x | 11.58x | 14.34x | 13.04x | 4.33x | 1.66x | 2.41x | 3.18x | 3.37x |
Goodwill | 10.8M | 11.63M | 15.03M | 15.03M | 15.03M | 15.03M | 15.03M | 15.03M | 15.03M |
Intangible Assets | 16.85M | 15.09M | 13.26M | 11.62M | 9.8M | 7.91M | 5.87M | 3.88M | 3.45M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 99K | 90K | 3.46M | 1.66M | 5.92M | 6.86M | 7.26M | 8.23M | 7.86M |
Total Assets | 39.06M▲ 0% | 41.63M▲ 6.6% | 121.07M▲ 190.8% | 76.1M▼ 37.1% | 92.91M▲ 22.1% | 99.1M▲ 6.7% | 97.24M▼ 1.9% | 87.48M▼ 10.0% | 94.64M▲ 0% |
Asset Turnover | 0.52x | 0.59x | 0.38x | 0.72x | 0.41x | 0.50x | 0.73x | 1.01x | 1.07x |
Asset Growth % | - | 6.6% | 190.8% | -37.15% | 22.09% | 6.66% | -1.87% | -10.04% | -38.21% |
Total Current Liabilities | 4.47M | 22.6M | 32.13M | 28.96M | 22.84M | 33.42M | 14.32M | 17.44M | 14.49M |
Accounts Payable | 886K | 1.72M | 8.96M | 1.66M | 1.69M | 2.93M | 2.19M | 3.08M | 3.65M |
Days Payables Outstanding | 73.4 | 103.18 | 148.73 | 19.88 | 43.45 | 82.17 | 51.42 | 51.32 | 93.39 |
Short-Term Debt | 0 | 12.16M | 11.84M | 19K | 49K | 51K | 21K | 1.37M | 1.45M |
Deferred Revenue (Current) | 492K | 1.28M | 3.53M | 1.85M | 962K | 324K | 678K | 961K | 4.57M |
Other Current Liabilities | 2.09M | 6.28M | 3.81M | 21.4M | 15.05M | 26M | 792K | 12.03M | 9.16M |
Current Ratio | 2.22x | 0.56x | 2.68x | 1.51x | 2.34x | 1.19x | 2.76x | 1.86x | 2.82x |
Quick Ratio | 2.06x | 0.53x | 2.58x | 1.41x | 2.27x | 1.15x | 2.76x | 1.86x | 2.82x |
Cash Conversion Cycle | 18.39 | 23.57 | 26.98 | 39.29 | 41.03 | 14.2 | - | - | -46.86 |
Total Non-Current Liabilities | 232.62M | 247.57M | 47.78M | 27.41M | 49.46M | 61.1M | 62.05M | 72.5M | 71.02M |
Long-Term Debt | 23.1M | 23.81M | 15.93M | 9.99M | 25M | 35.23M | 36.41M | 71.48M | 70.16M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 5.25M | 25.16M | 24.83M | 0 | 48.52M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -400K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 209.52M | 223.76M | 31.85M | 17.42M | 19.2M | 712K | 815K | 1.02M | 860K |
Total Liabilities | 237.09M | 270.17M | 79.9M | 56.37M | 72.3M | 94.52M | 76.37M | 89.94M | 85.5M |
Total Debt | 23.1M | 35.97M | 27.77M | 10.01M | 31.85M | 60.69M | 61.98M | 72.85M | 71.61M |
Net Debt | 17.18M | 30.68M | -34.36M | -22.7M | -11.24M | 34.41M | 35.73M | 53.87M | 46.04M |
Debt / Equity | - | - | 0.67x | 0.51x | 1.55x | 13.25x | 2.97x | - | 7.84x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -3.45x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -2.22x |
Interest Coverage | -7.97x | -9.21x | -3.12x | -8.57x | -7.11x | -4.47x | -4.20x | -3.57x | -4.47x |
Total Equity | -198.03M▲ 0% | -228.54M▼ 15.4% | 41.17M▲ 118.0% | 19.73M▼ 52.1% | 20.61M▲ 4.5% | 4.58M▼ 77.8% | 20.88M▲ 355.8% | -2.46M▼ 111.8% | 9.13M▲ 0% |
Equity Growth % | - | -15.41% | 118.01% | -52.08% | 4.46% | -77.77% | 355.81% | -111.81% | -332.28% |
Book Value per Share | -149.22 | -5.00 | 8.51 | 14.42 | 9.79 | 1.12 | 3.22 | -0.33 | 0.95 |
Total Shareholders' Equity | -198.03M | -228.54M | 41.17M | 19.73M | 20.61M | 4.58M | 20.88M | -2.46M | 9.13M |
Common Stock | 1K | 1K | 27K | 31K | 78K | 96K | 145K | 8K | 10K |
Retained Earnings | -200.14M | -230.86M | -258.81M | -301.97M | -367.42M | -419.57M | -462.5M | -497.76M | -505.56M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -5.57M | -193.96M | -121.07M | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDSX Cash Flow Statement
Biodesix, Inc. (BDSX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -17.68M | -21.73M | -21.37M | -28.22M | -44.97M | -22.87M | -48.65M | -23.27M | -24.84M |
Operating CF Margin % | -86.52% | -88.49% | -46.9% | -51.78% | -117.69% | -46.59% | -68.21% | -26.3% | - |
Operating CF Growth % | - | -22.91% | 1.66% | -32.09% | -59.35% | 49.15% | -112.72% | 52.17% | 182.25% |
Net Income | -26.17M | -30.73M | -31.35M | -43.16M | -65.45M | -52.15M | -42.93M | -35.27M | -31.96M |
Depreciation & Amortization | 1.74M | 2.79M | 2.9M | 3.18M | 5.84M | 5.51M | 5.46M | 5.6M | 5.58M |
Stock-Based Compensation | 142K | 170K | 3.71M | 4.94M | 5.96M | 5.37M | 6.64M | 4.14M | 4.28M |
Deferred Taxes | 47K | 0 | 1.6M | -2.1M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 6.31M | 7.68M | 6.58M | 4.33M | 13.01M | 7.09M | 3.86M | 1.92M | 1.47M |
Working Capital Changes | 253K | -1.65M | -4.8M | 4.59M | -4.34M | 11.3M | -21.67M | 334K | -4.21M |
Change in Receivables | -146K | -3.65M | -10.31M | 11.45M | -1.5M | -4.72M | -1.81M | -531K | -1.92M |
Change in Inventory | -389K | 0 | -11.65M | 7.42M | 906K | 166K | 22K | 0 | 0 |
Change in Payables | 342K | 1.19M | 11.65M | -7.42M | -773K | 513K | 1.64M | 0 | 3.8M |
Cash from Investing | -617K | -1.87M | -2.93M | -2.55M | -3.53M | -23.06M | -3.44M | -403K | -410K |
Capital Expenditures | -617K | -1.42M | -2.18M | -2.55M | -3.53M | -22.92M | -3.23M | -259K | -285K |
CapEx % of Revenue | 3.02% | 5.77% | 4.78% | 4.67% | 9.25% | 46.69% | 4.53% | 0.29% | 0.3% |
Acquisitions | 0 | -456K | -750K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -119K | 0 | 0 | 0 | 0 | -143K | -210K | -144K | -125K |
Cash from Financing | 19.03M | 22.97M | 81.13M | 1.26M | 58.88M | 29.13M | 52.05M | 16.42M | 33.22M |
Debt Issued (Net) | -12.65M | 13.04M | 16.04M | -15.35M | 16.5M | 9.95M | -51K | 9.98M | 10.01M |
Equity Issued (Net) | 8.5M | 10.05M | 72M | 16.34M | 59.54M | 28.13M | 55.63M | 7.82M | 24.54M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 23.18M | -116K | -6.91M | 269K | -17.15M | -8.95M | -3.52M | -1.38M | -1.33M |
Net Change in Cash | 738K▲ 0% | -628K▼ 185.1% | 56.84M▲ 9150.6% | -29.51M▼ 151.9% | 10.38M▲ 135.2% | -16.8M▼ 261.9% | -39K▲ 99.8% | -7.26M▼ 18507.7% | 7.97M▲ 0% |
Free Cash Flow | -18.29M▲ 0% | -23.04M▼ 25.9% | -23.54M▼ 2.2% | -30.77M▼ 30.7% | -48.51M▼ 57.6% | -45.93M▲ 5.3% | -51.88M▼ 12.9% | -23.67M▲ 54.4% | -25.23M▲ 0% |
FCF Margin % | -89.54% | -93.83% | -51.68% | -56.45% | -126.94% | -93.57% | -72.74% | -26.75% | -26.25% |
FCF Growth % | - | -25.92% | -2.2% | -30.7% | -57.64% | 5.31% | -12.95% | 54.37% | 44.26% |
FCF per Share | -13.79 | -0.50 | -4.87 | -22.49 | -23.04 | -11.19 | -8.00 | -3.14 | -2.61 |
FCF Conversion (FCF/Net Income) | 0.68x | 0.71x | 0.68x | 0.65x | 0.69x | 0.44x | 1.13x | 0.66x | 0.79x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BDSX Key Ratios
Biodesix, Inc. (BDSX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -76.16% | -141.75% | -324.53% | -414.09% | -337.3% | -383.09% | -2101.4% |
Return on Invested Capital (ROIC) | - | - | -1602.14% | -1186.56% | -128.25% | -54.13% | -38.71% | -35.02% |
Gross Margin | 75.26% | 51.71% | 44.01% | 62.96% | 73.5% | 78.17% | 75.25% | 59.86% |
Net Margin | -125.15% | -68.81% | -79.18% | -171.27% | -106.23% | -60.19% | -39.85% | -33.26% |
Debt / Equity | - | 0.67x | 0.51x | 1.55x | 13.25x | 2.97x | - | 7.84x |
Interest Coverage | -9.21x | -3.12x | -8.57x | -7.11x | -4.47x | -4.20x | -3.57x | -4.47x |
FCF Conversion | 0.71x | 0.68x | 0.65x | 0.69x | 0.44x | 1.13x | 0.66x | 0.79x |
Revenue Growth | 20.16% | 85.55% | 19.64% | -29.89% | 28.46% | 45.3% | 24.08% | 29.05% |
Related:BDSX Dividend History·BDSX Revenue History·BDSX Price History·BDSX P/E History·BDSX Financial Ratios·BDSX Institutional Holders
BDSX SEC Filings & Documents
Biodesix, Inc. (BDSX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BDSX Frequently Asked Questions
Biodesix, Inc. (BDSX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biodesix, Inc. (BDSX) reported $96.1M in revenue for fiscal year 2025. This represents a 370% increase from $20.4M in 2018.
Biodesix, Inc. (BDSX) grew revenue by 24.1% over the past year. This is strong growth.
Biodesix, Inc. (BDSX) reported a net loss of $32.0M for fiscal year 2025.
Dividend & Returns
Biodesix, Inc. (BDSX) has a return on equity (ROE) of -383.1%. Negative ROE indicates the company is unprofitable.
Biodesix, Inc. (BDSX) had negative free cash flow of $25.2M in fiscal year 2025, likely due to heavy capital investments.